Paratek Pharmaceuticals (PRTK) Stock Rating Upgraded by Zacks Investment Research

Paratek Pharmaceuticals (PRTK) Stock Rating Upgraded by Zacks Investment Research


The firm currently has a $16.00 target price on the specialty pharmaceutical company's stock. Zacks Investment Research 's target price points to a potential upside of 14.49% from the stock's current price.



from Biotech News